Analysis of U2 Small Nuclear RNA Fragments in the Bile Differentiates Cholangiocarcinoma from Primary Sclerosing Cholangitis and Other Benign Biliary Disorders
Analysis of U2 Small Nuclear RNA Fragments in the Bile Differentiates Cholangiocarcinoma from Primary Sclerosing Cholangitis and Other Benign Biliary Disorders
复制标题
DOI：
10.1007/s10620-014-3034-5
复制
发表时间：
2014-07-01
影响因子：
3.1
通讯作者：
Hahn, Stephan A.
中科院分区：
文献类型：
--
作者：
Baraniskin, Alexander;Noepel-Duennebacke, Stefanie;Hahn, Stephan A.
早期胆管癌的诊断一直是个难题，目前的诊断方法敏感性低。基于循环U2小核RNA片段（RNU2 - 1f）作为胰腺癌和结直肠癌新的血液生物标志物的最新研究结果，我们研究了RNU2 - 1f作为胆汁中CC诊断标志物的实用性。（胆总管结石患者）（n = 11）和原发性硬化性胆管炎（PSC; n = 11）。RNU2 - 1f水平通过实时聚合酶链反应测量，标准化为cel-54。在所有病例中，胆汁中RNU2 - 1f水平的测量能够区分CC患者和对照组。此外，CC患者胆汁中的RNU2 - 1f水平显著高于PSC患者，导致受试者工作特征曲线面积为0.856，敏感性为67%，特异性为91%。我们的数据表明，RNU2-胆汁中检测到的1片段可用作CC的诊断标志物，并应纳入该疾病实体的未来前瞻性诊断研究中。
Up to now the diagnosis of early stage cholangiocarcinoma (CC) has remained difficult, with low sensitivities reported for current diagnostic methods. Based on recent promising findings about circulating U2 small nuclear RNA fragments (RNU2-1f) as novel blood-based biomarkers for pancreatic and colorectal adenocarcinoma, we studied the utility of RNU2-1f as a diagnostic marker of CC in bile fluid.Bile fluid was collected from patients with CC (n = 12), controls (patients with choledocholithiasis) (n = 11) and with primary sclerosing cholangitis (PSC; n = 11). RNU2-1f levels were measured by real-time polymerase chain reaction normalized to cel-54.Measurement of RNU2-1f levels in bile fluids enabled the differentiation of patients with CC from controls in all cases. Furthermore, RNU2-1f levels in bile fluids of patients with CC were significantly higher than in patients with PSC, resulting in a receiver-operating characteristic curve area of 0.856, with sensitivity of 67 % and specificity of 91 %.Our data suggest that the measurement of RNU2-1 fragments detected in the bile fluid can be used as a diagnostic marker for CC and should be included in future prospective diagnostic studies for this disease entity.